Metabolic phenotypes predict survival in BCLC-C hepatocellular carcinoma receiving synchronous TACE plus targeted and immunotherapy

Liver cancer remains one of the most formidable challenges in modern medicine, particularly when it reaches an advanced stage where it has spread within the liver or to other parts of the body. For decades, doctors have relied on a procedure called transarterial chemoembolization, which involves blocking the blood supply to tumors and delivering chemotherapy directly into the liver. While this approach helped many, it often fell short for patients with the most aggressive disease. In recent years, the medical community has begun combining this local treatment with powerful new drugs that target the cancer's growth signals and boost the body's own immune system to fight the disease. This combination has shown great promise, extending lives significantly for many patients. However, a difficult reality persists: not everyone responds to this intensive treatment in the same way. Some patients thrive, living for years, while others see their disease progress rapidly despite receiving the exact same care. The central question facing doctors today is how to tell who will benefit before the treatment even begins, sparing some from aggressive therapies that may not work and ensuring others get the help they need.

A team of researchers set out to solve this puzzle by looking at the body's internal chemistry. They studied nearly 1,800 patients with advanced liver cancer who were treated with a combination of the local procedure and the new drug therapies. The researchers suspected that the answer lay not just in the size of the tumor or where it had spread, but in the metabolic state of the patient—their body's overall energy, nutritional status, and ability to handle the stress of the disease. By analyzing routine blood tests that are available in almost any hospital, they sought to find patterns that could predict who would survive the longest. They focused on specific markers in the blood, such as levels of proteins, enzymes that indicate cell stress, and minerals that reflect the body's balance. These simple numbers, they hypothesized, could reveal whether a patient's body was strong enough to withstand the treatment or if it was already too depleted to recover.

The researchers first confirmed that the new combination therapy was indeed a major step forward. After carefully matching patients to ensure a fair comparison, they found that those receiving the triple therapy lived a median of 28 months, compared to just 8 months for those who received the older treatment without the immune drugs. This was a dramatic improvement, yet the variation in outcomes remained wide. To understand why, the team used advanced computer analysis to group the patients based on their blood test results. Instead of looking at one number at a time, they let the data reveal natural groups of patients who shared similar metabolic profiles. This process sorted the patients into four distinct categories, ranging from those who were metabolically fit to those who were metabolically exhausted.

The first group, which the researchers called the "metabolically fit," made up the majority of the patients, about 59 percent. These individuals had blood markers indicating good nutritional health, balanced body chemistry, and a lower burden of disease stress. For this group, the treatment worked exceptionally well. They lived a median of 38 months, and more than four out of ten were still alive five years after starting treatment. This outcome is remarkable for a disease that was once considered nearly untreatable at this stage. The second group, the "metabolically compensated," represented about a quarter of the patients. They showed some signs of strain but still had enough reserve to respond to therapy, living a median of 21 months. The third group, labeled "tumor-metabolism dominant," comprised about 15 percent of the cohort. These patients had high levels of tumor activity that overwhelmed their body's ability to cope, resulting in a median survival of 15 months.

The final group, the "metabolically exhausted," was small, representing only about 2 percent of the patients, but their story was stark. These individuals showed signs of severe metabolic failure: their bodies were depleted of nutrients, their acid-base balance was disrupted, and their tumors were driving a massive energy crisis. For these patients, the intensive triple therapy offered almost no benefit. Their median survival was only 4 months, and fewer than 5 percent survived a year. This finding suggests that for this specific group, the standard aggressive approach might be too much for their bodies to handle, and they might be better served by different strategies or supportive care.

What makes this discovery particularly powerful is that it holds true across different types of patients. Whether a patient had cancer that had spread to other organs, whether they had a history of the disease returning, or whether they were older or younger, the metabolic profile remained a reliable guide. A patient with the "fit" profile did well regardless of these other factors, while a patient with the "exhausted" profile struggled regardless of their specific circumstances. The researchers identified eight specific blood factors that drove these differences: levels of a protein called alpha-fetoprotein, total protein, an enzyme called gamma-glutamyl transferase, an enzyme called lactate dehydrogenase, phosphorus, the presence of distant metastasis, bicarbonate, and red blood cell count. These are all standard tests that doctors order routinely, meaning this new way of looking at patients does not require expensive or rare equipment.

The study suggests that the body's ability to manage the stress of cancer and its treatment is just as important as the cancer itself. When the body has enough nutritional reserves and can maintain its chemical balance, it can withstand the powerful drugs and the local treatment. When those reserves are gone, the treatment becomes a burden the body cannot carry. By using these simple blood tests to identify a patient's metabolic state, doctors could potentially tailor their approach, offering the full triple therapy to those most likely to benefit and considering alternative paths for those who are too frail. This approach moves medicine closer to a future where treatment is chosen based on the unique biological reality of each patient, ensuring that the right person gets the right care at the right time.